Quanterix has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Simoa neurofilament light chain (NfL) plasma test for multiple sclerosis (MS).

The blood-based assay has obtained the designation as a prognostic aid for evaluating the disease activity risk in relapsing-remitting MS (RRMS) patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The digital immunoassay Simoa has been designed to quantitatively measure NfL in human serum and plasma.

Additionally, it can be used in conjunction with clinical, imaging and laboratory findings to identify RRMS patients at either lower or increased risk of relapse within four years.

Based on this information, the therapeutic approach for most effectively treating the disease can be determined.

Quanterix chairman and CEO Kevin Hrusovsky said: “For the more than two million people suffering from MS worldwide, there’s an important need for more informed and effective treatment options.

“Obtaining FDA breakthrough device designation for our plasma NfL MS test was a key objective for 2022.  We are pleased to have the opportunity to work with the FDA to help advance the Quanterix Simoa NfL test towards regulatory approval.”

The FDA’s designation follows a global study in which researchers at the University Hospital Basel and University of Basel, Switzerland, established a new approach to enable clinicians to identify and interpret high sNfL values in individual MS patients using the Simoa technology from Quanterix.

Quanterix noted that this is the company’s second test to receive Breakthrough Device status.

Last year, the company’s phospho-Tau 181 (pTau-181) assay for Alzheimer’s disease also received the designation.

In December 2020, the FDA issued an Emergency Use Authorization for Quanterix’s Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test.